目的 分析貝伐珠單抗不良反應(yīng)（ADR）發(fā)生率、發(fā)生類型和嚴(yán)重程度，為臨床安全合理使用提供參考。方法 采用文獻(xiàn)計(jì)量分析的方法，以“貝伐珠單抗”“安維汀”“阿瓦斯汀”“avastin”“bevacizumab”“不良反應(yīng)”“副作用”“adverse reaction”為關(guān)鍵詞，檢索萬方、中國知網(wǎng)、維普、PubMed、SpringerLink數(shù)據(jù)庫，采用Excel軟件建立數(shù)據(jù)庫，對(duì)ADR的類型、發(fā)生率及占比進(jìn)行統(tǒng)計(jì)分析。結(jié)果 共納入文獻(xiàn)171篇，1 024例患者共出現(xiàn)1 634例貝伐珠單抗ADR。最常見的ADR類型為骨髓抑制、高血壓、蛋白尿、出血；嚴(yán)重程度較高的ADR為動(dòng)靜脈栓塞、消化道穿孔、癲癇等。結(jié)論 臨床醫(yī)師或藥師在應(yīng)用貝伐珠單抗治療相關(guān)疾病時(shí)，應(yīng)重視其常見及嚴(yán)重的ADR。

Objective To analyze the incidence, types, and severity of adverse reactions (ADR) of bevacizumab, and to provide reference for safe and rational clinical use. Methods Using the method of bibliometric analysis, keywords "bevacizumab" "avastin" "avastin" "bevacizumab" "adverse reaction" "side effect" and "adverse reaction" were selected. The databases of Wanfang, CNKI, VIP, PubMed, and SpringerLink were searched, and excel software was used to establish the database. Types, incidence, and proportion of ADR were statistically analyzed. Results 171 related articles were finally included involving a total of 1 024 subjects and 1 634 cases of ADR. The most common ADR of bevacizumab included bone marrow suppression, hypertension, proteinuria, bleeding, etc. ADR with high severity include arteriovenous embolism, gastrointestinal perforation, epilepsy and so on. Conclusion Clinicians or pharmacists should pay attention to the common and serious ADR of bevacizumab in treatment of related diseases, and actively and correctly intervene the serious ADR.

R979.1